Company News
Company News
Media Reports
Honors & Rewards
Media Reports 
Good news! Kanglin's independently developed investigational gene therapy KL003 for β-thalassemia has made a major breakthrough and has been reported by various media outlets including CCTV.
Good news! Kanglin's independently developed investigational gene therapy KL003 for β-thalassemia has made a major breakthrough and has been reported by various media outlets including CCTV.
0571-86870039 
zhoujiahui@kanglinbio.com
4-301, No. 291, Fucheng Road, Xiasha Street, Qiantang District, Hangzhou 
Copyright © 2021-2022 康霖生物科技（杭州）有限公司
浙ICP备2022003670号-1
Kanexthal
Find Out More For β-thalassemia
